The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose
Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest.
Useful takeaways from this story.
Three federal pricing changes are about to land on a single outpatient claim.
The largest infusion and oncology programs will feel them first, and hardest.
Most of the 340B debate centers on rural hospitals and community health centers.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate centers on rural hospitals and community health centers.
How it works
- The biggest dollars, however, sit with academic medical centers (AMCs) and large health systems, and that is where Washington's next three moves converge.
- Starting January 1, 2027, hospitals buy drugs with Medicare-negotiated prices at wholesale acquisition cost (WAC) and wait for the 340B discount as a rebate.
- In 2028, negotiated prices reach Part B drugs administered in hospital infusion centers for the first time.</li...
Details worth keeping
In our August 17 analysis, 340B Rebates 2.0: HRSA Revives Its Pilot Program — and Sets Up a Collision Course With Congress, we mapped the competing reform tracks: HRSA's rebate pilot, Chairman Cassidy's 340B discussion draft and the bipartisan SUSTAIN 340B Act.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.